Biotechnology
Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements
NEW YORK, June 12, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerc...
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease
* HanAll Biopharma and Daewoong Pharmaceutical have co-invested in Vincere Biosciences. * These mission-aligned companies are collaborating to develop small-molecule therapies for Parkinson's patients, benefiting from their combined expertise in clinical development and disease biology. * T...
Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched
SHANGHAI, June 11, 2023 /PRNewswire/ -- On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform"). As one of the nine trillion antibody discovery platforms of San...
Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases
– Proceeds to support the development of Eccogene's clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders BOSTON and SHANGHAI, June 11, 2023 /PRNewswire/ -- Eccog...
ACROBiosystems Aneuro Partners with Diagnostic Biochips to Accelerate Neuroscience Drug Discovery
NEWARK, Del., June 9, 2023 /PRNewswire/ -- ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch ofin vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to ac...
E-Home Household Services Holdings Limited's subsidiary, Zhongrun Pharmaceutical Company, won the bid to represent Xi'an Liangjian Technology Company Limited, and the related performance is expected to reach RMB 10 million
FUZHOU, China, June 8, 2023 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, the Company today announced that after a fierce competition with a number of units, its holding company Zhongrun Pharmac...
IMBdx Expands Targeted Therapies Agreement Following Successful Evaluation of Blood-Based Genomic Profiling Assay in Prostate Cancer
SEOUL, South Korea, June 8, 2023 /PRNewswire/ -- IMBdx Inc., a premier precision cancer diagnostic company accredited by CAP, announced today its plans to broaden its collaboration with AstraZeneca, a leading global biopharmaceutical company. This expansion will advance the shift from tissue to ...
Sanyou's STAL helps researchers to explore the forefront of Life Sciences with high-impact literature publication
SHANGHAI, June 7, 2023 /PRNewswire/ -- Since the establishment of Super-Trillion Innovative Antibody Library (STAL), Sanyou has collaborated with or assisted scientists in publishing dozens of articles, of which 41 have a cumulative impact factor of 412.32, 14 papers have an impact factor greater...
ACROBiosystems expands custom GMP-grade protein services to drive CGT development and commercialization
NEWARK, Del., June 7, 2023 /PRNewswire/ -- Cell and gene therapy (CGT) is a cutting-edge therapy that combats cancer by bolstering the immune system through stem cell infusions or modified immune cells. However, manufacturing cell therapies is no easy feat. Cell therapy products have a higher R&D...
Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor
CAMBRIDGE, Mass., June 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to I™), today announced the appointment of Steve Arkinstall, D.Ph...
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023
SHENZHEN, China, June 6, 2023 /PRNewswire/ -- ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV (intravenous injection) in both U.S. andChina with all selected to be published (1 chosen for poster dis...
2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients
SHANGHAI and CHICAGO, June 6, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today published the latest results from the phase Ib/II study of GFH018 (TGF-β R1 inhibitor) with toripalimab(anti-PD-1 ...
Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025
- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters upon completion of the newest plant - Key features of Plant 5 include seamless ...
Acepodia Secures $100 Million Series D Financing to Advance
First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipeline, including ACE1831 and ACE2016, antibody armed allogeneic gamma ...
Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC
SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has release...
Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential
SUZHOU, China and ROCKVILLE, Md,, June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released preliminary results from a Phas...
Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries
* Subjects in Bunionectomy Study Dosed * Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 ...
Fresh2 Group Ltd. Announces US$4.4 Million Private Placement
NEW YORK, June 5, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...
Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies
SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase I...
Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX
SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00